{
    "id": "36394241-a534-5f29-e063-6394a90abc8b",
    "indications": "Valacyclovir hydrochlorideÂ is a nucleoside analogue DNA polymerase inhibitor indicated for: Adult Patients (1.1) Cold Sores (Herpes Labialis) Genital Herpes Treatment in immunocompetent patients (initial or recurrent episode) Suppression in immunocompetent or HIV-infected patients Reduction of transmission Herpes Zoster Pediatric Patients (1.2) Cold Sores (Herpes Labialis) Chickenpox Limitations of Use (1.3) The efficacy and safety of valacyclovir tablets, USP have not been established in immunocompromised patients other than for the suppression of genital herpes in HIV-infected patients.",
    "contraindications": "Valacyclovir tablets may be given without regard to meals.    \n                     \n                        Valacyclovir oral suspension (25 mg/mL or 50 mg/mL) may be prepared extemporaneously from 500 mg valacyclovir tablets for use in pediatric patients for whom a solid dosage form is not appropriate \n         \n   \n    [see \n          \n    \n     Dosage and Administration (2.3)]\n         \n   \n    .",
    "warningsAndPrecautions": "Valacyclovir Tablets USP, 1 gram  are blue, film-coated, capsule shaped tablets with a partial scorebar on both sides containing F on one side and 8 and 3 on the otherside.\n \n                  \n                  \n                  \n                  \n                  NDC 68071-1548-3 Bottles of 30\n                  \n                  \n                  \n                     \n                     \n                     \n                     Store at 20 \n  o to 25 \n  oC (68 \n  o to 77 \n  oF). [See USP Controlled Room Temperature.]\n  \n                     \n                     \n                     \nDispense in a well-closed container as defined in the USP.",
    "adverseReactions": "Valacyclovir tablets are contraindicated in patients who have had a demonstrated clinically significant hypersensitivity reaction (e.g., anaphylaxis) to valacyclovir, acyclovir, or any component of the formulation \n       \n \n  [see \n        \n  \n   Adverse Reactions (6.3)]\n       \n \n  .",
    "ingredients": [
        {
            "name": "CROSPOVIDONE",
            "code": "68401960MK"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POLYETHYLENE GLYCOL 400",
            "code": "B697894SGQ"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H"
        },
        {
            "name": "POVIDONE K90",
            "code": "RDH86HJV5Z"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "VALACYCLOVIR HYDROCHLORIDE",
            "code": "G447S0T1VC"
        }
    ],
    "organization": "NuCare Pharmacuticals,Inc.",
    "name": "Valacyclovir Hydrochloride",
    "effectiveTime": "20250528"
}